TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02229097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal bolus
Description: During the normal bolus period, the bolus will be adjusted to the carbohydrate content of each meal and injected immediately. The basal rate will remain at a normal level during the 3 hours postprandial period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal bolus
Description: During the normal bolus period, the bolus will be adjusted to the carbohydrate content of each meal and injected immediately. The basal rate will remain at a normal level during the 3 hours postprandial period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coordinated bolus
Description: The basal rate will be reduced at a rate of 0.1 U/h during the 3 h postprandial period. The insulin subtracted of the basal rate will be added to the normal bolus calculated for the meal and injected immediately.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coordinated bolus
Description: The basal rate will be reduced at a rate of 0.1 U/h during the 3 h postprandial period. The insulin subtracted of the basal rate will be added to the normal bolus calculated for the meal and injected immediately.
Study: NCT01683591

Intervention type: PROCEDURE
Intervention: High-resolution impedance manometry test
Description: The test was performed as general guideline for high-resolution impedance manometry test. The parameter was obtained and analyzed using the Chicago classification for the liquid swallows with Takasaki's modification for pharyngeal function monitoring. Swallowing pattern and aspiration risk were defined using real-time assessment of high-resolution impedance manometry test.
Study: NCT02129686

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate Acupuncture Group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Acupuncture Group
Study: NCT01312909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline 1mg BID
Description: Oral Varenicline 1mg BID, or 1/2 that dose (0.5mg BID) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline 0.5mg BID
Description: Oral Varenicline 0.5mg BID, or 1/2 that dose (0.5 QD) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo for twelve weeks,follow-up through Week 52
Study: NCT01566136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation Model of Care
Description: The PCRM-CI model includes the following 5 components: rehabilitation management; dementia management; delirium prevention and management; staff education and support; and family/significant other support and education.
Study: NCT02174536

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Decidual stromal cells
Description: Decidual stromal cells (approximately 1x10\^6 cells/kg) will be infused intravenously.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00753441

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical bypass
Description: Surgical bypass (choledochojejunostomy, in combination with gastroenterostomy if necessary)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic stenting
Description: Placement of a biliary metal stent (in combination with a duodenal metal stent in case of gastric outlet obstruction if necessary)
Study: NCT01513317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: 15 mg/kg administered as a 1-hour intravenous infusion every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as a 1-hour intravenous infusion every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Best supportive care (BSC)
Description: Best supportive care according to local standards and guidelines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Best supportive care (BSC)
Description: Best supportive care according to local standards and guidelines
Study: NCT01653431

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Study: NCT01816620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide, Dexamethasone
Description: 12 cycles of lenalidomide and dexamethasone, each cycle lasts 28 days. For patients with Ccr equal to or higher than 30ml/min, oral lenalidomide 10mg once daily for days 1-21 out of a 28 cycle.~For patients with Ccr lower than 30ml/min, oral lenalidomide 10mg once every other day for days 1-21 out of a 28 cycle.~All the patients take Dexamethasone orally 40mg once weekly for day 1,8,15,22 out of a 28 cycle.
Study: NCT01032694

Intervention type: DRUG
Intervention: Azithromycin SR
Description: Azithromycin SR, 2.0 g PO x 1 dose for treatment period

Intervention type: DRUG
Intervention: Amoxiclav
Description: Amoxiclav 1000 x twice daily, 10 days duration
Study: NCT02864017

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Enteral nutrition

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enteral nutrition

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Citrulline

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00637546

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Gait and Balance training based on recommendations of Robertson et al. and Page et al. (different balance control exercises; progression in consecutive stages: Sensimotor training, a static phase, a dynamic phase combined with functional tasks. The treatment takes place twice a week over 12 weeks. Patients were encouraged to perform specific home exercises.
Study: NCT01311830

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Counseling
Study: NCT03659617

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: xenograft (BioOss Collagen)
Description: Alveolar ridge preservation using xenograft (BioOss Collagen) and implant placement at 3 different time intervals (3, 6 and 9 months)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: xenograft (BioOss Collagen)
Description: Alveolar ridge preservation using xenograft (BioOss Collagen) and implant placement at 3 different time intervals (3, 6 and 9 months)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: xenograft (BioOss Collagen)
Description: Alveolar ridge preservation using xenograft (BioOss Collagen) and implant placement at 3 different time intervals (3, 6 and 9 months)
Study: NCT03489239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide
Description: subjects switching from Entecavir to single arm TAF 25mg
Study: NCT01889927

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: The exercise intervention will include aerobic, anaerobic, strength, core conditioning and stretching components.
Study: NCT01311830

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Written Materials
Study: NCT03063229

Intervention type: DEVICE
Group type: OTHER
Intervention: Accelerometer
Description: Attach a monitor to participants thigh to measure their physical activity for 7 days. The monitor is called the Activpal Micro.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accelerometer
Description: Attach a monitor to participants thigh to measure their physical activity for 7 days. The monitor is called the Activpal Micro.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accelerometer
Description: Attach a monitor to participants thigh to measure their physical activity for 7 days. The monitor is called the Activpal Micro.

Intervention type: OTHER
Group type: OTHER
Intervention: Anthropomentry
Description: Take skinfold measurements of participants using Harpenden skinfold calipers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anthropomentry
Description: Take skinfold measurements of participants using Harpenden skinfold calipers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anthropomentry
Description: Take skinfold measurements of participants using Harpenden skinfold calipers.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood tests
Description: Taking standard clinical blood tests to measure HbA1c, Glucose, FBC, U\&E's, LFT's, Coagulation Screen, Lipid Profile, Thyroid Function, and Tacrolimus for transplant patients.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood tests
Description: Taking standard clinical blood tests to measure HbA1c, Glucose, FBC, U\&E's, LFT's, Coagulation Screen, Lipid Profile, Thyroid Function, and Tacrolimus for transplant patients.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood tests
Description: Taking standard clinical blood tests to measure HbA1c, Glucose, FBC, U\&E's, LFT's, Coagulation Screen, Lipid Profile, Thyroid Function, and Tacrolimus for transplant patients.

Intervention type: DEVICE
Group type: OTHER
Intervention: BODPOD
Description: Measure body composition using a BODPOD machine. This uses Air displacement plethysmography.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BODPOD
Description: Measure body composition using a BODPOD machine. This uses Air displacement plethysmography.
Study: NCT01154673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir
Description: Raltegravir 400 mg BID + Maraviroc 150mg BID in addition to standard HAART

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maraviroc
Description: Raltegravir 400 mg BID + Maraviroc 150mg BID in addition to standard HAART
Study: NCT03063229

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BODPOD
Description: Measure body composition using a BODPOD machine. This uses Air displacement plethysmography.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI (Magnetic Resonance Imaging)
Description: MRI Scans of abdomen, particularly the livers of islet transplant and insulin pump patients.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI (Magnetic Resonance Imaging)
Description: MRI Scans of abdomen, particularly the livers of islet transplant and insulin pump patients.

Intervention type: OTHER
Group type: OTHER
Intervention: Food Diary
Description: Participants will keep a 7 day weighed food diary.
Study: NCT01154673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emtricitabine 200mg /tenofovir 300mg
Description: emtricitabine 200mg /tenofovir 300mg QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: emtricitabine 200mg /tenofovir 300mg
Description: emtricitabine 200mg /tenofovir 300mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir 400 mg/ritonavir 100mg
Description: lopinavir 400 mg/ritonavir 100mg BID
Study: NCT03063229

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Food Diary
Description: Participants will keep a 7 day weighed food diary.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Food Diary
Description: Participants will keep a 7 day weighed food diary.

Intervention type: DEVICE
Group type: OTHER
Intervention: CGMS (Continuous Glucose Monitoring System)
Description: Participants will wear a CGMS for 7 days to measure their glucose control and pattern over a 7 day period.
Study: NCT01154673

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lopinavir 400 mg/ritonavir 100mg
Description: lopinavir 400 mg/ritonavir 100mg BID
Study: NCT01850108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Day 9 before BMT: 0.5mg/kg IV; Days 8 \& 7 before BMT: 2mg/kg IV~Days 8 \& 7 - 2mg/kg IV before BMT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days 6 and 2 before BMT: 30mg/m2/day IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CTX)
Description: Days 6 and 5 before BMT: 14.5mg/kg IV; Days 3 and 4 after BMT: 50mg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Days 3 \& 4 after BMT: 40 mg/kg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Adjusted to maintain a serum trough level of 3-12 ng/mL, taken orally beginning on 5 days after BMT and taken to 1 year after BMT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Description: 15 mg/kg orally with maximum dose 3 mg/day beginning 5 days after BMT and taken to day 35 after BMT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation
Description: Day 0 - Transplantation of hematopoietic cells derived from bone marrow of a donor to a recipient as treatment for hematologic disorders

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: 200 cGy on the day before BMT. Radiation delivered to the entire body of the recipient to eradicate bone marrow cells in the recipient to prepare the recipient to receive the transplanted
Study: NCT05059717

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo standard of care MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MR DENSE imaging
Study: NCT02765542

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Automated disease assessment & self-care support phone calls
Description: Automated disease assessment \& self-care support phone calls for up to 12 weeks.
Study: NCT03311828

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imaging Agent
Description: Given Copper 64Cu-DOTA-daratumumab IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT01636258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culinary education
Description: Every other week
Study: NCT02637362

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ankle block
Description: Ultrasound guided ankle block of the tibial, superficial peroneal and deep peroneal nerves will be performed using a standardised technique
Study: NCT04064359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBT076, a CD205-directed antibody-drug conjugate
Description: Intravenous (IV) infusion of OBT076 every 3 weeks.
Study: NCT04541433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833
Description: AZD9833 taken orally
Study: NCT05754320

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tension band wire fixation
Description: Tension band wire fixation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plate fixation
Description: Tension band wire fixation
Study: NCT01557660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled treprostinil
Description: 0.6mg/mL inhalation solution, up to 12 breaths four times a day
Study: NCT03529526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN046
Description: The modified phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of KN046: 0.3 mg/kg,1 mg/kg,3 mg/kg,5 mg/kg,10 mg/kg.
Study: NCT03383432

Intervention type: DEVICE
Group type: OTHER
Intervention: Intrauterine device
Description: Copper T 380 A

Intervention type: DEVICE
Group type: OTHER
Intervention: Intrauterine device
Description: Copper T 380 A
Study: NCT02637362

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ankle block
Description: Ultrasound guided ankle block of the tibial, superficial peroneal and deep peroneal nerves will be performed using a standardised technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham ankle block
Description: In the supine position with the hip and knee flexed, and the hip externally rotated, the skin from medial malleolus to Achilles tendon will be prepared with chlorhexidine 0.5% solution and allowed to dry. An ultrasound probe (linear array HFL25, Sonosite, Hitchin, UK) will be placed on a line from medial malleolus to achilles tendon to identify the posterior tibial artery and tibial nerve. A Stimuplex A50 needle (B-Braun) will be placed against the skin at the point at which the practitioner would normally have performed insertion of the needle. It will remain there for a total of 30 seconds and then will be removed.
Study: NCT03383432

Intervention type: RADIATION
Group type: OTHER
Intervention: Ultrasound
Description: Transabdominal ultrasound

Intervention type: PROCEDURE
Group type: OTHER
Intervention: uterine sounding sparing technique
Description: we will insert intrauterine device without using the uterine sound and we will replace this step by ultrasound before insertion
Study: NCT03548844

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: local excision
Description: Pathologically verified ypT0-1cN0 rectal cancer patients after local excision are randomized to observation (local excision group) .

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total mesorectal excision
Description: Pathologically verified ypT0-1cN0 rectal cancer patients after local excision are randomized to complementary rectal excision (total mesorectal excision group).
Study: NCT00023673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study: NCT01149083

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT02637362

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Metatarsal block
Description: A metatarsal block will be performed using a standardised technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Metatarsal block
Description: A metatarsal block will be performed using a standardised technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham metatarsal block
Description: In the supine position, after the surgical incision has been sutured, a 25G standard bevel needle will be placed against the skin at the points at which the practitioner would normally have performed insertions of the needle. It will remain there for a total of 30 seconds and then be removed.
Study: NCT01149083

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study: NCT04366492

Intervention type: OTHER
Group type: OTHER
Intervention: Prevalence of blood borne viral infections (HBV/HCV/HIV)
Description: rapid finger prick test for HCV Ab, HBsAg and HIV and a questionnaire
Study: NCT01149083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study: NCT03735238

Intervention type: OTHER
Intervention: SMILE Computerized Decision-Aid
Description: SMILE is a computerized decision-aid designed to give lupus patients information about lupus, treatments for lupus available to them, as well as side effects. This will be administered at every lupus clinic session. Every patient will see the SMILE Computerized Decision-Aid at their index baseline clinic visit.
Study: NCT04288323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid
Description: This study involves an on-label use of Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid for the ....
Study: NCT00023673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study: NCT02766686

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy with protons

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy with photons

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiotherapy with photons
Study: NCT00954694

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NuStep fitness apparatus
Description: The NuStep is a mode of exercise that has recently been used in clinical settings to determine appropriate intensity recommendations and energy expenditures. The NuStep exercise implement provides simultaneous upper and lower body movement while in a seated position. The machine stimulates all major muscle groups while putting minimal strain on joints. Ten resistance settings are offered and the device is fully adjustable to accommodate users of varying sizes (NuStep, 2009).
Study: NCT03345485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine 60mg/m2 over 30min
Description: Tinostamustine as a single agent was administered at doses of 60mg/m2 by intravenous infusion over 30 minutes on Days (D) 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine 80mg/m2 over 30min
Description: Tinostamustine as a single agent was administered at doses of 80mg/m2 by intravenous infusion over 30 minutes on Days (D) 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine 100mg/m2 over 30min
Description: Tinostamustine as a single agent was administered at doses of 100mg/m2 by intravenous infusion over 30 minutes on Days (D) 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine 60mg/m2 over 60min
Description: Tinostamustine as a single agent was administered at doses of 60mg/m2 by intravenous infusion over 60 minutes on Days (D) 1 and 15 of each 28-day cycle.